sFRP4 peptides

sFRP4 peptides are research-stage micropeptides derived from the two functional domains of the Secreted Frizzled-Related Protein 4 (sFRP4) — specifically its cysteine-rich domain (CRD) and netrin-like domain (NLD). These peptides function as Wnt pathway antagonists by inhibiting the binding of Wnt ligands to Frizzled receptors, thereby suppressing the Wnt/β-catenin signaling pathway. Primarily investigated for their potential in oncology, these peptides target cancer stem cells (CSCs) and have demonstrated the ability to initiate apoptosis, inhibit cell migration, suppress autophagy, and chemosensitize resistant tumor cells. Research has focused on various aggressive cancers, including malignant mesothelioma, ovarian cancer, glioblastoma multiforme, and head and neck cancers. One notable peptide variant, SC-401, has been identified as particularly effective in diminishing the properties of therapy-resistant tumor-initiating cells.

Other names

secreted frizzled-related protein 4 peptidessFRP4-derived peptidessFRP-4-derived peptidessFRP 4-derived peptidessFRP4 micropeptidessFRP-4 micropeptidessFRP 4 micropeptides